Silence Therapeutics plc has entered into a transaction agreement with Merck KGaA, Darmstadt, Germany, to be acquired for $6.67 per share. This acquisition, announced on October 18, 2026, represents a pivotal moment for the company and underscores the ongoing consolidation trend in the pharmaceutical preparations industry.
The agreement stipulates that all ordinary shares of Silence Therapeutics will be transferred to Merck KGaA, with shareholders receiving $6.67 in cash for each share held. For holders of American Depositary Shares (ADS), which represent three ordinary shares, the payout will be $20.00 per ADS. This deal has been recommended by Silence's board of directors.
Background
Silence Therapeutics plc, incorporated in England and Wales, operates in the pharmaceutical preparations sector (SIC: 2834). The company is publicly traded on the Nasdaq under the ticker SLN and also has shares available on the OTC market under SLNCF. Recent filings include a DEFA14A and another 8-K, both filed on October 19, 2026.
What the Filing Says
The filing states, "On October 18, 2026, Silence Therapeutics plc... entered into a transaction agreement with Merck KGaA... The Transaction Agreement provides... that Purchaser will acquire the entire issued and to be issued share capital of the Company... pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006." It further details the cash consideration for shareholders and the conditions required for the transaction to proceed.
Impact
This acquisition will affect various stakeholders, including Silence's shareholders, who will receive cash for their shares, and employees, who may face changes as the company integrates into Merck KGaA. The transaction is also significant for the pharmaceutical preparations sector, indicating a trend toward consolidation as larger firms seek to expand their portfolios through acquisitions.
What's Next
The transaction is subject to several conditions, including approval by Silence's shareholders and regulatory approvals. A special resolution must be passed by a majority representing at least 75% of the voting rights at the upcoming shareholder meetings. The filing does not specify what happens next beyond these approvals.